Sahajanand Medical Technologies Ltd. IPO Review, Financial Analysis & Valuation

Incorporated in October 2001, Sahajanand Medical Technologies Limited is a medical technology company engaged in the development, manufacturing, and marketing of technologically advanced medical devices. The company primarily focuses on vascular intervention and structural heart intervention. Its product portfolio includes coronary stents, coronary balloons, transcatheter aortic valve implantation (TAVI) devices, occluders, renal stents, and peripheral drug-coated balloons (DCBs). The company focuses on research and development, precision manufacturing, and clinically supported product innovation. Its flagship brands include Supraflex Cruz, Cocoon, and Hydra, which cater to different areas of interventional cardiology. It operates three manufacturing facilities, with two located in India and one in Thailand, supported by two R&D centres across India and Thailand. As of June 30, 2026, the company had 119 patents granted globally, 78 patent applications in the pipeline, and five design registrations in India. In Fiscal 2026, its products were marketed across 77 countries using direct, hybrid, and distributor-led models. Through these channels, it has established a market presence in India, Europe, and other international markets. The company reported revenue from operations of ₹12,105.04 million in Fiscal 2026, compared with ₹10,248.79 million in Fiscal 2025 and ₹9,016.04 million in Fiscal 2024. As of June 30, 2026, its team included 1,605 full-time employees, 31 consultants, and 707 contract-based employees.